Cyclo Therapeutics Total Current Liabilities Over Time
| CYTH Stock | USD 0.64 0.08 11.11% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cyclo Therapeutics Performance and Cyclo Therapeutics Correlation. Cyclo |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Liabilities Analysis
Compare Cyclo Therapeutics and related stocks such as Cue Biopharma, Tff Pharmaceuticals, and Lantern Pharma Total Current Liabilities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CUE | 342.2 K | 342.2 K | 342.2 K | 342.2 K | 342.2 K | 342.2 K | 1.1 M | 5.3 M | 6.2 M | 11.7 M | 16.3 M | 12.8 M | 11.5 M | 17.1 M | 10.1 M |
| TFFP | 11 K | 11 K | 11 K | 11 K | 11 K | 11 K | 11 K | 1.8 K | 1.2 M | 410.6 K | 1.3 M | 2 M | 1.1 M | 2.4 M | 2.5 M |
| LTRN | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 489.3 K | 552.3 K | 2.3 M | 2.8 M | 2.7 M | 1.7 M |
| INBX | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 5.3 M | 8.9 M | 16.2 M | 20.6 M | 31.4 M | 22.5 M | 27.6 M | 56.3 M | 59.1 M |
| ELVN | 826 K | 826 K | 826 K | 826 K | 826 K | 826 K | 826 K | 826 K | 1.8 M | 4.2 M | 1.5 M | 5.8 M | 9.7 M | 25.9 M | 27.2 M |
| MOLN | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.1 M | 26.4 M | 15.8 M | 14.1 M | 36.9 M | 28.6 M | 57.7 M | 46.9 M | 17.3 M | 14.4 M | 13.7 M |
| ANEB | 223.9 K | 223.9 K | 223.9 K | 223.9 K | 223.9 K | 223.9 K | 223.9 K | 223.9 K | 223.9 K | 223.9 K | 241.6 K | 512.5 K | 534.5 K | 260.6 K | 390.1 K |
Cyclo Therapeutics and related stocks such as Cue Biopharma, Tff Pharmaceuticals, and Lantern Pharma Total Current Liabilities description
Total Current Liabilities is an item on Cyclo Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cyclo Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.My Equities
My Current Equities and Potential Positions
| Cyclo Therapeutics | CYTH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Florida; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.64
Check out Cyclo Therapeutics Performance and Cyclo Therapeutics Correlation. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Cyclo Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.